Psychological Status and Quality of Life in relation to the Metabolic Syndrome: Isfahan Cohort Study by Roohafza, Hamidreza et al.
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2012, Article ID 380902, 5 pages
doi:10.1155/2012/380902
Clinical Study
PsychologicalStatus andQuality of Lifeinrelation to the
Metabolic Syndrome:Isfahan CohortStudy
Hamidreza Roohafza,1 Masoumeh Sadeghi,2 Mohammad Talaei,1
ZahraPourmoghaddas,3 andNizal Sarrafzadegan1
1Cardiovascular Research Center, Isfahan Cardiovascular Research Institute (WHO-Collaborating Center),
Isfahan University of Medical Sciences, 81465-1148 Isfahan, Iran
2Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute (WHO-Collaborating Center),
Isfahan University of Medical Sciences, P.O. Box 81465-1148, Isfahan, Iran
3Child Health Promotion Research Center, School of Medicine, Isfahan University of Medical Sciences, 81465-1148 Isfahan, Iran
Correspondence should be addressed to Masoumeh Sadeghi, m sadeghi@crc.mui.ac.ir
Received 19 November 2011; Revised 18 March 2012; Accepted 18 March 2012
Academic Editor: Stephen L. Atkin
Copyright © 2012 Hamidreza Roohafza et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objective. Current study was designed to investigate the association of metabolic syndrome (MetS) with depression, anxiety,
psychological distress, and quality of life (QoL). Design. Two hundred and ﬁfteen contributors with MetS and 253 participants
without MetS were randomly selected from 2151 participants of Isfahan Cohort Study who were residents of Isfahan
city. Measurements consisted of fasting blood samples, anthropometrics, and self-reported data of 12-item General Health
Questionnaire, Hospital Anxiety and Depression Scale, and European Quality of Life-5 Dimension. Binary logistic regression
analysis was used to ﬁnd the association between MetS and four psychological factors. Results. Participants mean age was
56.3±9.8 years. Male/female ratio was 0.86 (217/251). Mean score of depression (P = 0.003), anxiety (P = 0.018), distress
(P = 0.047), and QoL (P ≤ 0.001) was signiﬁcantly higher in MetS group. There were signiﬁcant increasing relationships between
depression (OR1.10, 95% CI1.03–1.22), anxiety (OR1.03, 95% CI1.05–1.11), and QoL (OR1.13, 95% CI1.05–1.23) and MetS
when associations were adjusted for other risk factors, but it was not the case for distress (OR1.03, 95% CI0.99–1.08). Conclusion.
It might be better to consider MetS as a combination of biological and psychological risk factors. Thus, a person with metabolic
disease should be recognized as a patient with these factors and be screened for all of them.
1.Introduction
Assuming that psychological status aﬀects all medical condi-
tions, researchers have focused on these psychological status’
roles especially on noncommunicable disease with almost
unknown origin [1]. The relationship of depression, anxiety,
and psychological distress with chronic metabolic disease
suchasdiabetesmellitus,insulinresistance,anddyslipidemia
has been established [2]. Metabolic syndrome (MetS) is
a combination of metabolic risk factors such as impaired
glucoselevel,dyslipidemia,hypertension,andcentralobesity
that predispose persons to cardiovascular mortality and
morbidity [3]. Obvious causes for this chronic condition
have not been introduced and contributory factors in MetS
have been receiving attention [4].
There are conﬂicting results about probable association
of MetS with psychological problems. For instance, it was
shown that MetS associated with long-term depressive
symptoms [5, 6], while another study reported absence of
any association between MetS, depression and anxiety [7].
Other lines of evidence have introduced prolong exposure to
chronic psychological distress as an important risk factor for
MetS and have claimed there is an association between daily
lifestressorsandmetabolicsyndrome[8];however,empirical
data on this ﬁeld is little and needs more evaluation. On
the other hand, the relationship of lower physical well-being
and social function as indicators of QoL with MetS has
been shown [9]; however, a study ascribed this association
to obesity rather than MetS [10]. In general, ﬁndings about
association of MetS and poor quality of life (QoL) are scarce.2 International Journal of Endocrinology
MetS prevalence in Iranian population comparing with
other Asian societies is high, varied from 11% of young
adolescents under twenty years of age to 33% of persons who
aged more [11, 12]. The global belief of this high prevalence
is socioeconomic and demographics changes [13]. Similarly,
the number of Iranian patients who suﬀer from anxiety,
depression,andpsychologicaldistressishigh[14].Therefore,
we aimed to investigate association of depression, anxiety,
psychological distress, and quality of life with metabolic
syndrome in a sample of Iranian as a population with high
prevalence of MetS.
2.Methods and Materials
This cross-sectional study was designed among participants
of Isfahan Cohort Study (ICS). ICS is a population-based
cohort study on 6504 participants who were ≥35 years
old from three counties of central Iran (Isfahan, Arak,
Najafabad) [15, 16], which started in 2001, for detecting
mortality, morbidity, and risk factors of cardiovascular
disease. Approvals were made with the bioethical committee
of the Provincial University of Medical Sciences. Informed
consents were obtained from participants of both groups.
There were 1520 subjects available in Isfahan city from
which 599 participants met Adult Treatment Panel III
(ATPIII) criteria for detecting Mets at baseline that was
described in details elsewhere [17]. It was calculated that
254 subjects in each group would be required to detect a
diﬀerence of at least 1 (eﬀect size) in scores of psychological
factors between MetS and non-MetS groups with 80% power
(β = 0.2) at the 2-tailed 0.025 level of signiﬁcance (α = 0.05)
and standard deviation of 4 in both groups. Using random
sampling procedure in SPSS, 254 individuals with MetS and
the same number without it were selected and invited for
ﬁllingquestionnairesandnewanthropometricandbiochem-
ical measurements. The response rate in MetS group was
lowerthannon-MetSgroup(86.6%versus96.4%);therefore,
the sample size of control group was increased to 300
subjectsusingthisequation:1/ncase+1/ncontrol = 2/ncalculation.
According to the new measurements, 5 participants did not
fulﬁll ATPIII criteria for MetS anymore. In turn, 47 subjects
without history of MetS based on baseline measurements
met MetS criteria based on new measurements. In order to
evaluatepersistentMetS,theseindividualswereexcludedand
215 subjects with MetS and 253 without it were included in
analysis. Power analysis was carried out using G∗Power 3.1.3
(18) for the GHQ12 scores as the factor with the weakest
association in this study (Table 2). Considering the actual
sample size and real ﬁndings on this score, the minimum
power of study was calculated as 81.7% (post hoc power
analysis).
2.1. Measurements. Body weight and height were measured
with indoor clothing and light slipper. Waist circumference
(WC) was measured by tape, horizontally 1cm above the
navel. Blood pressure was taken two times after ﬁve minutes
resting in calm and comfortable room with 15-minutes
interval; ﬁnally mean of two blood pressure recordings was
used for analysis. Triglyceride (TG), fasting plasma glucose
(FPG), and high-density lipoprotein cholesterol (HDL-
C) were detected by an enzymatic method in Elan 2000
autoanalyzer. Friedewald formula was used for calculating
low-density lipoprotein cholesterol (LDL-C) level except
in individuals with TG ≥ 400mg/dL which LDL-C level
was measured directly. Participants who used at least one
cigarette per day were considered as current smokers.
Self-administered 12-item General Health Questionnaire
(GHQ12) was used for assessing distress [18, 19]. Less
than usual, no more than usual, fairly more than usual, or
much more than usual were answers to questions of this
questionnaire, which were scaled as GHQ score method (0-
0-1-1 method). According to this method sum of answers
to total items were scored on a scale ranging from 0 to
12. Participants with higher score was considered as higher
psychological distress.
Anxiety and depression were evaluated by the Hospital
Anxiety and Depression Scale (HADS) [20, 21]. The HADS
is a 14-item questionnaire consisting of two anxiety and
depression subscales; each one includes seven items. Four
point scale used for rating anxiety and depression, ranged
f r o m0t o2 1w i t hac u t - o ﬀ value of 7. In each subscales,
higher score showed higher anxiety and depression.
Self-administered instrument European Quality of Life-
5 Dimensions (EQ-5D) was used to evaluate QoL [22].
Five dimensions of health including mobility, self-care, usual
activity, pain/discomfort and anxiety/depression were evalu-
ated by this instrument. Three levels of severity presented for
each domain as 1 (No problems), 2 (some problems), and
3 (extreme problems). Global QoL score of participants was
deﬁned by the combinations of dimensions’ score. Higher
EQ-5D scores indicate poor QoL.
2.2. Statistical Analysis. Data entry was done using Epi Info,
Version 6 (Centers for Disease Control, Atlanta, GA). Data
were analyzed by SPSS software, version 15 (SPSS Inc,
Chicago, IL). A P value ≤ 0.05 was considered statistically
signiﬁcant for all analyses. Student’s t-test for continuous
variables and chi-square test for discrete variables were used.
Binary logistic regression analysis was used to ﬁnd
the association among the MetS and four psychological
variables. Odds ratios (OR) were reported with the corre-
sponding 95% conﬁdence intervals. Independent variables
included scores of depression, anxiety, distress, and QoL, as
well as smoking, body mass index (BMI), total cholesterol,
age,sex,andeducation.DependentvariablewasMetS.Linear
regression analyses were used to evaluate the relationship
of each psychological variable with the number of MetS
components as dependent variable.
3. Results
The mean age of all participants in present study was 56.3 ±
9.8 years. Male/female ratio was 0.86 (217/251) (Table 1).
In non-MetS group, 55 (21.7%), 95 (37.5%), and 103
(40.8%) participants had 0, 1, and 2 components of MetS,
respectively. In MetS group, 133 (61.8%), 66 (30.7%) andInternational Journal of Endocrinology 3
Table 1: Baseline characteristics according to the presence or absence of metabolic syndrome.
Non-MetS (n = 253) MetS (n = 215) P-value
Mean ± SD Mean ± SD
Age 56.3 ±9.55 6 .5 ± 9.4 0.791
Male, n (%) 148 (58.4%) 69 (32.1%) <0.001
Current smoking, n (%) 41 (16.2%) 21 (9.7%) <0.001
Fasting plasma glucose (mg/dL) 84.0 ±19.7 113.3 ± 48.1 <0.001
Waist circumference (cm) 89.1 ±9.69 9 .9 ± 9.1 <0.001
Body mass index (kg/m2)2 7 .1 ±4.13 1 .5 ± 4.9 <0.001
Systolic blood pressure (mm/Hg) 120.8 ±18.5 131.0 ± 16.8 <0.001
Diastolic blood pressure (mm/Hg) 77.8 ±8.18 1 .8 ± 9.1 <0.001
Low-density lipoprotein cholesterol (mg/dL) 118.6 ±25.2 120.4 ± 27.8 0.463
High-density lipoprotein cholesterol (mg/dL) 48.4 ±11.64 1 .6 ± 9.3 <0.001
Total cholesterol (mg/dL) 206.3 ±38.7 217.3 ± 45.2 0.007
Triglycerides (mg/dL) 144.5 ±68.7 263.9 ± 67.4 <0.001
Table 2:Psychologicalvariableaccordingtothepresenceorabsence
of metabolic syndrome.
Non-MetS (n = 253) MetS (n = 215) P-value
Mean ± SD Mean ± SD
Depression score 9.04 ±3.09 9.96 ±3.32 0.003
Anxiety score 4.56 ±4.27 5.59 ±4.77 0.018
GHQ score 2.05 ±1.52 2.42 ±1.60 0.047
EQ5-QOLscore 6.69 ±1.45 7.25 ±1.47 <0.001
16 (7.4%) individuals were detected that had 3, 4, and 5
component, respectively.
Seventy persons (32.5%) in MetS group and 7 (2.7%)
individuals in non-MetS group had FPG ≥ 110mg/dL
(P<0.001). One hundred and ninety three (89.7%) subjects
in MetS group and 86 (33.9%) in non-MetS group had
TG ≥ 150mg/dL (P<0.001). In MetS group, 171 (79.5%)
individuals had low HDL-C level (<40mg/dL for men and
<50mg/dL for women), but it was detected only in 86
(33.9%) subjects in non-MetS group (P<0.001). High WC
(≥102cm in men and ≥88cm in women) was detected in
167 (77.6%) and 48 (19%) participants in MetS and non-
MetS group, respectively (P<0.001). Likewise, 143 (66.5%)
and 81 (32%) participants in these groups had high blood
pressure (systolic blood pressure ≥130 or diastolic blood
pressure ≥85), respectively (P<0.001).
Mean score of depression, anxiety, distress, and Qol was
signiﬁcantly higher in MetS group as were represented in
Table 2. As shown in Table 3, the multivariate logistic regres-
sion analysis after adjusting for demographic risk factors,
showed the signiﬁcant association of depression, anxiety,
distress, and quality of life score with MetS. By adjusting age,
sex, smoking, BMI, and cholesterol, distress role attenuated
but depression, anxiety, and QoL role signiﬁcantly remained
in the model.
Figure 1 illustrates signiﬁcant worsening trends of scores















Number of MetS components
Depression P = 0.007
EQ5-QOL P = 0.001
Anxiety P = 0.035
Stress P = 0.777
Figure 1: Psychological variable according to the number of
metabolic syndrome components.
components increased; however, distress scores did not show
this pattern. Among components of MetS, central obesity
was signiﬁcantly associated with detrimental increase of all
fourpsychologicalfactors(P<0.001exceptforGHQ-12that
P = 0.03).DepressionscoreandQoLweresigniﬁcantlylower
in high FPG (P = 0.002, P = 0.008). Conversely, GHQ-12
score was slightly lower in those without TG component of
MetS (P = 0.037). There were rare reports of drugs that have
eﬀect on mood (n = 15, including 8 for TCAs, 4 for sodium
valproate, and 6 for SSRIs, some reported concurrent use of
2d r u g s ) .4 International Journal of Endocrinology
Table 3: Unadjusted and fully adjusted ORs of psychological Factors with metabolic syndrome.
Unadjusted Age and sex adjusted Fully adjusted∗
OR (95% CI) OR (95% CI) OR (95% CI)
Depression score 1.23 (1.07–1.41)‡ 1.17 (1.06–1.34)‡ 1.10 (1.03–1.22)†
Anxiety score 1.12 (1.04–1.21)† 1.11 (1.05–1.19)† 1.03 (1.05–1.11)†
GHQ score 1.08 (1.03–1.12)† 1.04 (1.02–1.18)† 1.03 (0.99–1.08)
EQ5-QOL score 1.47 (1.29–1.69)§ 1.24 (1.07–1.44)‡ 1.13 (1.05–1.23)†
∗Adjusted for age, sex, smoking, BMI and total cholesterol.
†P < 0.05, ‡P < 0.01, §P < 0.001.
4. Discussion
Present study participants with clinically veriﬁed MetS had a
signiﬁcant higher score for depression, anxiety, and distress.
This study showed individuals with MetS had impaired QoL.
Current study suggested the association between MetS
and depression. In line with our ﬁndings, a community-
based study [23] found that MetS is associated with self-
perceived depression. In a cohort study [24], MetS could
predict depression. While another research [5] on depressed
patients indicated the association of long-term depressive
symptoms and emergence of MetS, R¨ aikk¨ oonen et al. [6]
have shown in their study that psychological factors play
causal role in MetS. Hence, it seems there is a two-way street
between depression and MetS.
In spite of diﬀerent study methods, our results are in
agreement with R¨ aikk¨ onen et al. [25] and Carroll et al. [26]
and showed that anxiety is associated with MetS in both
sexes. Other ﬁndings of R¨ aikk¨ onen’s studies demonstrated
that feeling intense, anger, and distress increased risk for
MetS [6, 25]. Furthermore, other researchers [8]h a v e
suggested emergence of MetS after 5 years exposure to high
psychological distress. Statistically signiﬁcant association of
our participants’ distress with MetS was lost after adjusting
for BMI, smoking, age, sex, and cholesterol level. Diﬀerent
measurement methods of psychological distress, type of
research, study population, and adjusting factors in present
study compared to R¨ aikk¨ onen et al. researches may justify
these diﬀerences.
Our ﬁndings showed that individuals with MetS had
impaired QoL in terms of health, mobility, self-care, usual
activity, pain/discomfort, and anxiety/depression, even after
controllingconfoundingfactors.Twodiﬀerentstudies[9,13]
have demonstrated that people with MetS have impaired
QoL including physical and social function as well as general
and mental health. Although studies about QoL and MetS
are few, but present study ﬁndings were in accordance with
them and have suggested impaired quality of life in patients
with MetS.
Somemechanismsweresuggestedaspossiblyresponsible
for association of psychological disorders, impaired QoL and
MetS. First mechanism is biological alternation [27]s u c h
as autonomic nervous system changes like heart rate vari-
ability, dysregulation of endocrine organ like hypothalamic-
pituitary-adrenal axis, and alternation of inﬂammatory
and hemostatic markers and neurotransmitters especially
blunted level of serotonin [6]. Second mechanism is sep-
arated correlation of psychological problems with MetS
components, for instance, association of depression with vis-
ceral fat accumulation, insulin resistance, and dyslipidemia
[2]. Last one is the similar risk factors of psychological,
and metabolic disorders [9], for example, low intensity of
leisure time physical activity, unhealthy dietary habits, high
consumption of alcohol, and low education, and so forth.
Thisstudybeneﬁtedfromparticipantswithwiderangeof
age, enough sample size, and recruiting individuals who had
MetS for about 7 years. However, some limitations should be
considered. First, self-reported questionnaires such as HADS
give limited data about participants’ depression and anxiety
at one time but no information about lifetime psychological
problems. Second, in spite of wide level of adjustment in
analyses of present study, it is still possible that unmeasured
confounders interfere with part of the association between
MetS and psychological disorders. Third, recall bias may
occur because participants with MetS may report poorer
social and emotional situation because of the syndrome. In





of psychological problem such as depression, anxiety, psy-
chological distress, and impaired Qol. Thus, a person with
metabolic disease should be recognized as a patient with
biological, psychological, and environmental risk factors and
screened for all of them.
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